Atlas Trials

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Clinical trial NCT03319667 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03319667
Sponsor
Sanofi
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Plasma Cell Myeloma
Start date
2017-12-07
Primary completion
2027-04-05
Enrollment
475

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.